Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 104.39% | 57.91% | 81.14% | -350.13% | 421.89% |
| Total Depreciation and Amortization | 2.00% | 3.13% | 20.04% | -23.88% | 12.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 767.35% | -105.12% | -70.99% | 2,943.09% | 79.58% |
| Change in Net Operating Assets | 7.58% | -175.81% | 195.83% | 172.09% | 34.97% |
| Cash from Operations | 563.35% | -103.47% | 73.67% | 16.64% | 1,122.15% |
| Capital Expenditure | 45.47% | 25.35% | -107.81% | -91.55% | -43.88% |
| Sale of Property, Plant, and Equipment | -- | -94.88% | -96.96% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.01% | 152.11% | -601.25% | -109.27% | 726.95% |
| Cash from Investing | -1.60% | 147.53% | -1,193.40% | -105.24% | 752.64% |
| Total Debt Issued | 119.28% | 37.06% | -- | -100.00% | 87.53% |
| Total Debt Repaid | 61.63% | -203.03% | 78.41% | -261.01% | 43.07% |
| Issuance of Common Stock | 31.76% | 359.46% | -22.11% | 7.95% | -16.19% |
| Repurchase of Common Stock | -99.19% | -- | -- | -94.07% | 29.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 84.73% | -264.09% | 80.39% | -443.06% | 77.68% |
| Cash from Financing | 65.33% | -286.42% | 91.81% | -213.15% | 49.05% |
| Foreign Exchange rate Adjustments | 124.98% | -388.05% | -53.94% | 1,003.20% | -110.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 740.52% | -149.05% | 122.04% | -146.48% | 315.71% |
